E
Elisa de Stanchina
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 268
Citations - 26387
Elisa de Stanchina is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 65, co-authored 201 publications receiving 21076 citations. Previous affiliations of Elisa de Stanchina include Kettering University & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega,Jaclyn F. Hechtman,Pau Castel,Geoffrey Y. Ku,Yaelle Tuvy,Helen Won,Christopher J. Fong,Nancy Bouvier,Gouri Nanjangud,Joanne Soong,Efsevia Vakiani,Mark A. Schattner,David P. Kelsen,Robert A. Lefkowitz,Karen T. Brown,Mario E. Lacouture,Marinela Capanu,Marissa Mattar,Besnik Qeriqi,Fabiola Cecchi,Yuan Tian,Todd Hembrough,Rebecca J. Nagy,Richard B. Lanman,Steven M. Larson,Neeta Pandit-Taskar,Heiko Schöder,Christine A. Iacobuzio-Donahue,David H. Ilson,Wolfgang A. Weber,Michael F. Berger,Elisa de Stanchina,Barry S. Taylor,Jason S. Lewis,David B. Solit,Jorge A. Carrasquillo,Maurizio Scaltriti,Nikolaus Schultz,Yelena Y. Janjigian +38 more
TL;DR: Analysis of patients with ERBB2-amplified, trastuzumab-resistant EG cancer who were treated with the HER kinase inhibitor afatinib revealed that sensitivity and resistance to therapy were associated with EGFR/ERBB2 coamplification and MET amplification, respectively.
Journal ArticleDOI
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
Eiki Ichihara,David Westover,Catherine B. Meador,Yingjun Yan,Joshua A. Bauer,Pengcheng Lu,Fei Ye,Amanda Kulick,Elisa de Stanchina,Robert McEwen,Marc Ladanyi,Darren Cross,William Pao,Christine M. Lovly +13 more
TL;DR: It is reported that Src family kinases (SFK) and focal adhesion kinase (FAK) sustain AKT and MAPK pathway signaling under continuous EGFR inhibition in osimertinib-sensitive cells, and the concomitant inhibition of both SFK/FAK and EGFR may be a promising therapeutic strategy for EGFR-mutant lung cancer.
Journal ArticleDOI
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose escalation clinical trial
Jason J. Luke,David R. D'Adamo,Mark A. Dickson,Mary Louise Keohan,Richard D. Carvajal,Robert G. Maki,Elisa de Stanchina,Elgilda Musi,Samuel Singer,Gary K. Schwartz +9 more
TL;DR: The sequential combination of doxorubicin followed by flavopiridol is well tolerated on both schedules and disease control was observed in well- and dedifferentiated liposarcoma specifically, a disease in which CDK4 is known to be amplified.
Journal ArticleDOI
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein,Robert M. Samstein,Robert M. Samstein,Chirag Krishna,Xiaoxiao Ma,Xin Pei,Ken-Wing Lee,Vladimir Makarov,Fengshen Kuo,Jonathan H. Chung,Raghvendra M. Srivastava,Tanaya A. Purohit,Douglas R. Hoen,Rajarsi Mandal,Jeremy Setton,Wei Wu,Rachna Shah,Besnik Qeriqi,Qing Chang,Sviatoslav M. Kendall,Lior Z. Braunstein,Britta Weigelt,Pedro Blecua Carrillo Albornoz,Luc G. T. Morris,Diana Mandelker,Jorge S. Reis-Filho,Elisa de Stanchina,Simon N. Powell,Timothy A. Chan,Nadeem Riaz +29 more
TL;DR: In this paper, the effects of mutations in the homologous recombination genes BRCA1 and bRCA2 on response to immunotherapy in mouse and human tumors were investigated.
Journal ArticleDOI
Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
Yelena Y. Janjigian,Nerissa Viola-Villegas,Jason P. Holland,Vadim Divilov,Sean Carlin,Erica M. Gomes-DaGama,Gabriela Chiosis,Gregory Carbonetti,Elisa de Stanchina,Jason S. Lewis +9 more
TL;DR: Afatinib demonstrated antitumor activity in HER2-positive gastric cancer in vivo and demonstrated the pharmacodynamic effects of afatinib in NCI-N87 xenografts using 89Zr-trastuzumab and 18F-FDG PET.